Searched for
TEVA API LTD
Glenmark Life Sciences IPO sails through on Day 1Most analysts are positive on the company's future prospects and suggest subscribing to the issue. They believe the company, which is a spi...- Glenmark Life Sciences IPO opens today: Should you subscribe?Considering the FY-21 adjusted EPS of Rs 28.69 on post issue basis, the upper price band of Glenmark Life Sciences IPO implies a P/E of 25....
- NGT imposes Rs 10 crore fine on pharma company Teva APIThe tribunal said that violation in the matter of illegal extraction of groundwater is clearly established along the pollution of the drain.
- Buy Neuland Laboratories, target Rs 920: HDFC SecuritiesNeuland Laboratories is a smallcap company, operating in pharmaceuticals and health care sector.
- Dr Reddy's hires former Teva exec to lead the businessHis knowledge and experience from leading pharmaceutical businesses of scale will be valuable for our future growth,” said G.V. Prasad CEO ...
- India Inc's Oct foreign borrowing down 24% at $2.11 bnIndia Inc raised over $2.11 billion from overseas markets in October 2015, down 24.1 per cent from the same month a year ago, RBI data show...
- Teva-Allergan deal a booster for Indian companiesTeva Pharmaceutical Industries’ $40.5-billion purchase of Allergan’s generics business may help Indian generic-drug makers acquire products
- Exports to Europe from Ranbaxy's two plants to remain suspendedExports from Ranbaxy plants at Toansa and Dewas to Europe will remain suspended as probes are continuing, European health regulator EMA sai...
- Pharmaceutical firm Teva API to set up unit in Indore SEZ; to invest 1000 crorePharmaceutical firm Teva API India plans to invest about Rs 1,000 crore over the next five years in setting up of a formulation unit in the...
- Teva Pharmaceuticals will not be launching Atorvastatin, generic version of LipitorIsrael's Teva Pharmaceuticals will not launch atorvastatin, the generic version of Lipitor, that will help Indian cos Ranbaxy and Dr Reddy'...
- Cipla expected to report 34% gain in Q4 net profitCIPLA is expected to report a 34% YoY increase in its Q4 net profit at Rs 286 crore compared to Rs 214 crore in the year ago period, accord...
- Ranbaxy launches low-cost version of medicine 'Lipitor'The US FDA allowed Ranbaxy to make and sell atorvastatin tablets, the chemical name of Lipitor, ending months of uncertainty.
- Franklin Templeton PE invests Rs 45 cr in drug-maker Symbiotec PharmalabSymbiotec is engaged in research, development, manufacturing and marketing of research-based active pharmaceutical ingredients for corticos...
- Zydus, Teva end patent disputesAhmedabad-based ZydusCadila and Israeli generic major Teva have settled their patent disputes over active pharmaceutical ingredients (APIs)...
- Teva, Glenmark call an end to patent disputeIsraeli generic major Teva and Mumbai-based Glenmark Pharmaceuticals have settled a patent dispute over various generic versions of Coreg -...
- Drug firms fight with foreign cos over patentsPharma companies are at loggerheads with their foreign counterparts over patent rights. Global pharma giants have been filing cases against...
- Zydus drags Teva to court for antitrust violationsZydus Cadila, an Ahmedabad-based pharmaceutical company, has taken Teva Pharmaceuticals, the world’s largest generic drug maker, to court i...
- TEVA TO buy local unit for Rs 400 crThe world’s largest generic drug manufacturer Teva may be close to acquiring domestic company Saraca Labs’ manufacturing plant in Hyderabad...
- DRL expects verdict in Aciphex case by May 15As the patent clash between Dr Reddy's Labs (DRL) and Japanese pharma firm Eisai for the control over $1.3-billion anti-ulcer drug Aciphex ...
- Teva exploring prospects in Indian marketThe world’s largest generic drug maker Teva Pharmaceuticals is investigating the Indian market and examining what value proposition it can ...
Load More
